ALX Oncology Holdings

ALXO · NASDAQ

$1.24+$0.10 (+8.77%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.14

ALXO analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $4.69 (+278.4% upside)

Low: $4.04
Now: $1.24
High: $6.30

Upgrades and downgrades

The latest rating actions, newest first

ALXO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Mar 19, 2026	Initiates	Overweight	$5.00	54%
HC Wainwright & Co.	Mar 10, 2026	Maintains	Buy	$4.00	43%
Piper Sandler	Feb 5, 2026	Maintains	Overweight	$3.00 → $4.00	55%

The case for and against

Updated Oct 22, 2025

Bull case

ALX Oncology Holdings Inc. is poised for significant revenue growth, with projections indicating an increase from $45 million in 2032 to $278 million by 2034, showcasing a strong upward trajectory in its financial outlook. The company's strategic decisions have successfully extended its cash runway into the fourth quarter of 2026, allowing for focused investment in its clinically de-risked breast and colorectal cancer programs utilizing the CD47 blocker, evorpacept. This combination of projected revenue growth and extended cash runway highlights the company's potential for sustained development and innovation in the immuno-oncology space.

Bear case

ALX Oncology Holdings Inc reported a net loss of $0.58 per share for 1Q25, which exceeded the consensus estimate of a $0.47 loss per share, reaffirming concerns about the company's financial health amidst a lack of revenue. Furthermore, the decision to discontinue evaluations of its candidate Evo for head and neck squamous cell carcinoma and bladder cancer, due to subpar clinical data, highlights potential challenges in advancing its product pipeline. The FDA's request for a Phase 3 study, citing insufficient data from the Phase 2 ASPEN-06 study for accelerated approval, further compounds the company's negative outlook by indicating potential delays and additional costs in achieving regulatory milestones.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.